ATLANTA, GA – – (Newsfile Corp. – December 1, 2021) – – Holzer & Holzer, LLC is investigating whether TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) complied with federal securities laws. On November 30, 2021, TG Therapeutics provided a regulatory update, advising that “the U.S. Food and Drug Administration (FDA) has notified the Company that it plans to host a meeting of the Oncologic Drugs Advisory Committee (ODAC) in connection with its review of the pending Biologics License Application (BLA)/supplemental New Drug Application (sNDA).” The Company further indicated that the “FDA’s concern giving rise to the ODAC meeting appears to stem from an early analysis of overall survival from the UNITY-CLL trial.” On this news, the Company’s stock dropped. If you purchased TG Therapeutics stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.